What changed in Cencora, Inc.'s latest annual report
In the year ended 30 Sep 2025, Cencora, Inc.'s revenue rose 9.3% to USD 321.33bn, from USD 293.96bn; net income rose 3% to USD 1.55bn, from USD 1.51bn; shareholders' equity rose 133.5% to USD 1.51bn, from USD 645.94m.
Year ended 30 Sep 2025. Source: 10-K filed 25 Nov 2025, read it on SEC EDGAR.
USD 293.96bn to USD 321.33bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 293.96bn | 321.33bn | Up 9.3% |
| Net income | 1.51bn | 1.55bn | Up 3% |
| Total assets | 67.10bn | 76.59bn | Up 14.1% |
| Long-term debt | 3.81bn | 7.54bn | Up 97.9% |
| Cash and cash equivalents | 3.13bn | 4.36bn | Up 39.1% |
| Shareholders' equity | 645.94m | 1.51bn | Up 133.5% |
Questions people ask
Did Cencora, Inc.'s revenue grow last year?
Revenue grew 9.3%, from USD 293.96bn to USD 321.33bn in the year ended 30 Sep 2025.
Is Cencora, Inc. profitable?
Yes. Net income was USD 1.55bn in the year ended 30 Sep 2025. The year before: USD 1.51bn.
How much cash and debt does Cencora, Inc. have?
At its latest year end (30 Sep 2025), Cencora, Inc. reported cash and cash equivalents of USD 4.36bn and long-term debt of USD 7.54bn.
Where do these numbers come from?
From Cencora, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Cencora, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Wholesale-Drugs, Proprietaries & Druggists' Sundries companies
- McKESSON CORPORATIONNet income up 44.5%
- Cardinal Health, Inc.Cash and cash equivalents up 25.3%